# US 2021/0196838 A1 · Compounds and compositions for potentiation of tlr agonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0196838 A1
- Document ID: US20210196838A1
- Status: Published application
- Kind: A1
- Application number: 17/271,071
- Filed: 2019-08-23
- Published: 2021-07-01
- Earliest claimed: 2018-08-24
- Applicants: Mirexus Biotechnologies Inc.
- Inventors: Jondavid DE JONG; Stephanie DEWITTE-ORR; Karl Michael KLINGER; Emily MOORE; Sheetij GHOSHAL; Anton KORENEVSKI
- Web page: https://patentgrep.com/patent/US20210196838A1

## CPC

- A61K 47/6939: {the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin}
- A61K 9/5161: {Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin}
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- A61K 2039/55561: {CpG containing adjuvants; Oligonucleotide containing adjuvants}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to novel Toll-like Receptor (TLR) agonist compositions that can demonstrate enhanced innate immune responses, improved stability and lower toxicity than said agonists alone. These immunomodulators comprise one or more TLR agonists linked to glycogen-based nanoparticles. Also provided are processes for manufacturing, and methods of using the compositions to induce therapeutic immune responses.

## Claims

### Claim 1

An immunomodulator for enhancing the innate immune response comprising: a TLR agonist covalently or non-covalently linked to glycogen-based polysaccharide nanoparticles having a molecular weight of 106 to 107 Da comprising α-D glucose chains, having an average chain length of 11-12, with 1→4 linkage and branching point occurring at 1→6 and with a branching degree of between 6% and 13%.

### Claim 2 (depends on 1)

The immunomodulator of claim 1, wherein the TLR agonist is selected from: double-stranded RNA, double-stranded DNA and single-stranded RNA, single-stranded DNA, or any synthetic analogs thereof including poly IC, CpG ODN, LNA.

### Claim 3 (depends on 1)

The immunomodulator of claim 1, wherein the TLR receptor is located in an endosome.

### Claim 4 (depends on 1)

The immunomodulator of claim 1, wherein the TLR receptor is located at the cell surface.

### Claim 5 (depends on 1)

The immunomodulator of claim 1 wherein the TLR agonist comprises between about 60% and 600% by weight relative to the polysaccharide nanoparticles.

### Claim 6 (depends on 1)

The immunomodulator of claim 1, wherein the nanoparticles have a polydispersity index (PDI) of less than about 0.3 as measured by dynamic light scattering and an average particle diameter of between about 10 nm and 150 nm.

### Claim 7 (depends on 1)

The immunomodulator of claim 1, wherein the nanoparticles are further covalently linked to one or more small molecules for directing the nanoparticles to a type of cell or cellular compartment.

### Claim 8 (depends on 1)

The immunomodulator of claim 1 wherein the TLR agonist is covalently linked to the nanoparticles through a linking group.

### Claim 9 (depends on 1)

The immunomodulator of claim 1 wherein the nanoparticles are cationic and the TLR agonist is non-covalently linked to the nanoparticles through electrostatic interactions.

### Claim 10 (depends on 1)

A pharmaceutical composition comprising the immunomodulator of claim 1 and a pharmaceutically acceptable excipient.

### Claim 11 (depends on 10)

The pharmaceutical composition of claim 10 wherein the composition is a powder, tablet or capsule.

### Claim 12 (depends on 10)

The pharmaceutical composition of claim 10 wherein the composition is a vaccine.

### Claim 13 (depends on 10)

The pharmaceutical composition of claim 10 further comprising an antiviral agent, an anticancer agent, a further immunomodulator, or a vaccine.

### Claim 14 (depends on 1)

A method of stimulating an innate immune response in a subject comprising administering to the subject a therapeutically effective amount of an immunomodulator according to claim 1.

### Claim 15 (depends on 14)

The method of claim 14, wherein the immunomodulator is administered by intramuscular, oral, sublingual, buccal, parenteral, nasal, subcutaneous, intradermal, or topical administration.

### Claim 16 (depends on 14)

The method of claim 14 for preventing or treating a viral infection in the subject.

### Claim 17 (depends on 14)

The method of claim 14 for cancer immunotherapy.

### Claim 18

A method of potentiating a TLR agonist comprising covalently or non-covalently linking the TLR agonist to glycogen-based polysaccharide nanoparticles having a molecular weight of 106 to 107 Da comprising α-D glucose chains having an average chain length of 11-12, with 1→4 linkage and branching point occurring at 1→6 and with a branching degree of between 6% and 13%.

### Claim 19 (depends on 18)

The method of claim 18, wherein the nanoparticles are cationized.

### Claim 20 (depends on 18)

The method of claim 18 wherein the TLR agonist is selected from: double-stranded RNA, double-stranded DNA and single-stranded RNA, single-stranded DNA, or any synthetic analogs thereof including poly IC, CpG ODN, LNA.
